Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

Prevent osteoporosis by understanding low bone density, risk factors, prevention strategies, and treatment options for ...

Researchers treated postmenopausal women with osteoporosis with teriparatide biosimilar RGB-10, which improved their bone health measures and reduced fracture risk comparably to reference teriparatide ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.

including osteoporosis (OP). However, limited information was known about the correlation between OP and heavy metals, especially in postmenopausal women. The current research was aimed to explore the ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, ...

The drug also is used to treat postmenopausal osteoporosis when alternative treatments are not suitable. Fresenius Kabi Calcitonin Salmon Injection is formulated, filled and packaged in the United ...